INM has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
INM has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-06-10), InMed Pharmaceuticals's current share price is $0.2354. InMed Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was $36.34. InMed Pharmaceuticals's Cyclically Adjusted PB Ratio for today is 0.01.
The historical rank and industry rank for InMed Pharmaceuticals's Cyclically Adjusted PB Ratio or its related term are showing as below:
During the past years, InMed Pharmaceuticals's highest Cyclically Adjusted PB Ratio was 1.06. The lowest was 0.01. And the median was 0.04.
INM's Cyclically Adjusted PB Ratio is ranked better thanThe Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.
InMed Pharmaceuticals's adjusted book value per share data for the three months ended in Mar. 2024 was $1.750. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $36.34 for the trailing ten years ended in Mar. 2024.
The historical data trend for InMed Pharmaceuticals's Cyclically Adjusted PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InMed Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Cyclically Adjusted PB Ratio | Get a 7-Day Free Trial | 0.03 | 0.03 | 0.02 | 0.01 | 0.01 |
For the Biotechnology subindustry, InMed Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, InMed Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:
* The bar in red indicates where InMed Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.
Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.
InMed Pharmaceuticals's Cyclically Adjusted PB Ratio for today is calculated as
Cyclically Adjusted PB Ratio | = | Share Price | / | Cyclically Adjusted Book per Share |
= | 0.2354 | / | 36.34 | |
= | 0.01 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InMed Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:
For example, InMed Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:
Adj_Book | = | Book Value per Share | / | CPI of Mar. 2024 (Change) | * | Current CPI (Mar. 2024) |
= | 1.75 | / | 126.2576 | * | 126.2576 | |
= | 1.750 |
Current CPI (Mar. 2024) = 126.2576.
InMed Pharmaceuticals Quarterly Data
Book Value per Share | CPI | Adj_Book | |
201406 | 30.701 | 99.473 | 38.968 |
201409 | 25.469 | 99.394 | 32.353 |
201412 | 18.123 | 98.367 | 23.262 |
201503 | 18.123 | 99.789 | 22.930 |
201506 | 18.210 | 100.500 | 22.877 |
201509 | 12.915 | 100.421 | 16.238 |
201512 | 9.835 | 99.947 | 12.424 |
201603 | 6.790 | 101.054 | 8.484 |
201606 | 9.914 | 102.002 | 12.272 |
201609 | 10.654 | 101.765 | 13.218 |
201612 | 13.352 | 101.449 | 16.617 |
201703 | 22.380 | 102.634 | 27.531 |
201706 | 39.585 | 103.029 | 48.510 |
201709 | 37.295 | 103.345 | 45.564 |
201712 | 70.271 | 103.345 | 85.851 |
201803 | 61.452 | 105.004 | 73.890 |
201806 | 99.594 | 105.557 | 119.125 |
201809 | 96.104 | 105.636 | 114.865 |
201812 | 85.386 | 105.399 | 102.284 |
201903 | 77.829 | 106.979 | 91.854 |
201906 | 66.480 | 107.690 | 77.942 |
201909 | 54.226 | 107.611 | 63.622 |
201912 | 44.285 | 107.769 | 51.882 |
202003 | 32.543 | 107.927 | 38.070 |
202006 | 28.147 | 108.401 | 32.783 |
202009 | 21.520 | 108.164 | 25.120 |
202012 | 27.108 | 108.559 | 31.527 |
202103 | 32.339 | 110.298 | 37.018 |
202106 | 22.908 | 111.720 | 25.889 |
202109 | 36.850 | 112.905 | 41.208 |
202112 | 25.053 | 113.774 | 27.802 |
202203 | 19.055 | 117.646 | 20.450 |
202206 | 13.953 | 120.806 | 14.583 |
202209 | 12.113 | 120.648 | 12.676 |
202212 | 9.016 | 120.964 | 9.411 |
202303 | 3.722 | 122.702 | 3.830 |
202306 | 3.633 | 124.203 | 3.693 |
202309 | 2.878 | 125.230 | 2.902 |
202312 | 2.253 | 125.072 | 2.274 |
202403 | 1.750 | 126.258 | 1.750 |
Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.
Thank you for viewing the detailed overview of InMed Pharmaceuticals's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Jonathan Tegge | officer: Interim CFO | 217 W. MAIN STREET, SOMERVILLE NJ 08876 |
Sarah Li | officer: VP, Accounting and Controller | 310-815 WEST HASTINGS ST., VANCOUVER Z4 V6C1B4 |
Nicole Lemerond | director | 3 MURRAY HILL ROAD, SCARSDALE NY 10583 |
Bryan T Baldasare | director | 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244 |
Eric A Adams | director, officer: President & CEO | C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4 |
Brenda Edwards | officer: Interim CFO | 111-1232 JOHNSON ST., COQUITLAM A1 V3B 4T2 |
Janet P Grove | director | 510 WEST GEORGIA STREET, SUITE 1800, VANCOUVER A1 V5T 4T5 |
Bruce Colwill | officer: CFO | C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4 |
Shane Aaron Johnson | officer: SVP & GM of BayMedica LLC | 930 TAHOE BLVD., SUITE 802-433, INCLINE VILLAGE NV 89451 |
Adam D. Cutler | director | 9301 AMBERGLEN BOULEVARD, SUITE 100, C/O MOLECULAR TEMPLATES, INC., AUSTIN TX 78729 |
William J Garner | director | 875 MAHLER ROAD, SUITE 235, BURLINGAME CA 94010 |
Catherine Sazdanoff | director | 3471 RIVER HILLS DRIVE, CINCINNATI OH 45244 |
Eric C Hsu | officer: Sr. VP, Pre-Clinical Res/Dev | C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4 |
Michael Woudenberg | officer: VP, Chem/Manufacturing/Control | C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4 |
Mancini Alexandra Diane Janet | officer: Sr VP, Clinical Reg Affairs | C/O INMED PHARMACEUTICALS INC., SUITE 310 - 815 HASTINGS STREET, VANCOUVER A1 V6C 1B4 |
From GuruFocus
By Value_Insider Value_Insider • 11-10-2022
By PurpleRose PurpleRose • 07-18-2022
By GuruFocusNews GuruFocusNews • 07-09-2022
By GlobeNewswire GlobeNewswire • 07-13-2022
By GuruFocusNews GuruFocusNews • 06-16-2022
By Stock market mentor Stock market mentor • 01-10-2023
By sperokesalga sperokesalga • 02-10-2023
By GuruFocusNews GuruFocusNews • 06-24-2022
By Value_Insider Value_Insider • 11-17-2022
By GuruFocusNews GuruFocusNews • 07-02-2022